The news of 43 confirmed cases of post-marketing Natalizumab-related PML coincides with the timely publication of the description of the first 28 such cases and a review on the topic:
These developments underpin the urgent efforts to implement an appropriate risk-stratification strategy to lower the risks of developing PML for people with MS receiving Natalizumab.
Please watch this space for an update.